This trial is evaluating whether Psilocybin will improve 3 primary outcomes and 24 secondary outcomes in patients with Major depressive disorder, recurrent episode. Measurement will happen over the course of Up to 2 weeks.
This trial requires 30 total participants across 2 different treatment groups
This trial involves 2 different treatments. Psilocybin is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"While some patients were remarkably improved, the effect of psilocybin for the treatment of PD was still unsatisfactory. These data suggest that the psilocybin therapy is still a promising new therapeutic method for PD, but further studies are needed to clarify the mechanism of action with psilocybin-induced symptomatology." - Anonymous Online Contributor
"Although the mechanism underlying the improvement of depression after medical treatment is not fully elucidated, antidepressant medications are an effective and effective method in treating depression even if the patient is not completely cured." - Anonymous Online Contributor
"Treating physicians need to be vigilant toward a depressive disorder diagnosis to implement effective treatment for depression and provide adequate psychological support for their patients. In addition, the impact of depression on the quality of lives of the patients with depression and their willingness for effective treatment of depression should always be considered." - Anonymous Online Contributor
"A large proportion of subjects were not treated or only given medication and CBT as first line. Effective treatment and better compliance to treatment would be more effective for people with depressive disorder, especially when with treatment-resistant symptomatology." - Anonymous Online Contributor
"Signs of the depressive disorder include persistent sadness and hopelessness that interfere with the daily life. There is a strong connection between depression and exhaustion. Depressive disorder occurs in patients who had been diagnosed with a mental illness (mainly in depressed patients), who had been given different treatment strategies, including the antidepressant therapy." - Anonymous Online Contributor
"Although the exact mechanism underlying treatment-resistant depression is not clear, there is evidence that this may be part of the mechanisms underlying other chronic disorders. Attention to non-adherence to treatment as well as maintenance of a regular routine may reduce the risk that treatment-resistant depression will not respond as expected to treatment." - Anonymous Online Contributor
"About 700,000 to 1.3 million people suffer from a first episode of depression that worsens without treatment a year. This can be prevented with early initiation of treatment using agents that are effective in preventing recurrence." - Anonymous Online Contributor
"Psilocybin has a wide variety of effects with low overall side-effect rate. These effects span over most physiological systems, including the central nervous system, but also include gastrointestinal symptoms such as aldate and nausea. Most side effect events are thought to be secondary rather than direct effects of the drug." - Anonymous Online Contributor
"While the majority of DMR in this sample of BD and MDD were found to have a positive family history, the prevalence of DMR in these groups was not statistically different, suggesting that DMR is possibly not a specific PD subtype. However, for a subgroup of BD patients with DMR, a positive family history was statistically associated with more severe current disability and a more frequent recurrence of depressive episodes throughout their illness course." - Anonymous Online Contributor
"There has been a shortage of efficacious, stable antidepressant medications in the last 7 years. This shortage has been cited as one reason for a high number of depressed patients not presenting for treatment. There is a need for clinical study investigating the safety and efficacy of newer antidepressants in the treatment of patients with treatment-resistant depression." - Anonymous Online Contributor
"Evidence-based treatments for depression have improved over time, but depression remains a major psychiatric health issue, with a very high number of patients not improving after receiving the recommended treatments." - Anonymous Online Contributor
"Results from a recent trial examining the effects of psilocybin are encouraging, but a more thorough and carefully designed clinical trial would greatly benefit the field. ClinicalTrials.gov identifier: NCT00223038." - Anonymous Online Contributor